Smith+Nephew launches up to $250 million share buyback first tranche

Smith & Nephew Snats ( (SNN) ) just unveiled an update.

On 8 May 2026 Smith+Nephew, the London- and New York-listed medical technology group, announced details of the first tranche of a share buyback programme authorised at its 2026 annual general meeting. The company, which focuses on orthopaedics, sports medicine, ENT and advanced wound management products, said the initiative is intended to return surplus capital to investors and ultimately reduce its issued share capital.

Under a non-discretionary agreement with Merrill Lynch International acting as riskless principal, Smith+Nephew plans to repurchase up to $250 million of ordinary shares between 8 May and 7 September 2026, within a maximum of 84,988,930 shares. The stock bought will be held in treasury and either cancelled or used to satisfy employee share plans, with purchases conducted on recognised exchanges under UK market abuse and listing rules, though the company cautioned that there is no guarantee the full programme will be executed and that American depositary receipts will not be repurchased.

The most recent analyst rating on (SNN) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, operating across orthopaedics, sports medicine and ENT, and advanced wound management. Founded in Hull in 1856, it employs around 17,000 people, operates in about 100 countries, and generated $6.2 billion in sales in 2025 as a constituent of the FTSE 100 index.

The group’s portfolio targets improving patient outcomes through surgical and wound-care technologies, and it positions itself as an innovation-led supplier to healthcare providers worldwide. Listed in London and New York under tickers SN and SNN respectively, it serves hospitals and clinics globally with a broad suite of medical devices and related solutions.

Average Trading Volume: 992,022

Technical Sentiment Signal: Hold

Current Market Cap: $12.9B

See more insights into SNN stock on TipRanks’ Stock Analysis page.